%0 Journal Article
%A Chagtai, Tasnim
%A Zill, Christina
%A Dainese, Linda
%A Wegert, Jenny
%A Savola, Suvi
%A Popov, Sergey
%A Mifsud, William
%A Vujanić, Gordan
%A Sebire, Neil
%A Le Bouc, Yves
%A Ambros, Peter F
%A Kager, Leo
%A O'Sullivan, Maureen J
%A Blaise, Annick
%A Bergeron, Christophe
%A Mengelbier, Linda Holmquist
%A Gisselsson, David
%A Kool, Marcel
%A Tytgat, Godelieve A M
%A van den Heuvel-Eibrink, Marry M
%A Graf, Norbert
%A van Tinteren, Harm
%A Coulomb, Aurore
%A Gessler, Manfred
%A Williams, Richard Dafydd
%A Pritchard-Jones, Kathy
%T Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
%J Journal of clinical oncology
%V 34
%N 26
%@ 1527-7755
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2017-01742
%P 3195 - 3203
%D 2016
%X Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series.WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest.One hundred sixty-seven (28
%K Biomarkers, Tumor (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27432915
%2 pmc:PMC5505170
%R 10.1200/JCO.2015.66.0001
%U https://inrepo02.dkfz.de/record/125616